- Home
- SD vs BNTC Comparison
SD vs BNTC Comparison
Compare SD & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | BNTC |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 454.2M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SD | BNTC |
|---|---|---|
| Price | $14.63 | $12.19 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 251.6K | 180.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 12.43 | ★ 80.94 |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $12.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.10 | $9.85 |
| 52 Week High | $18.45 | $16.76 |
Technical Indicators
Market Signals| Indicator | SD | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 45.01 |
| Support Level | $14.37 | $11.41 |
| Resistance Level | $15.71 | $13.55 |
| Average True Range (ATR) | 0.33 | 0.72 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 71.14 | 22.39 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.